Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Revenue projections:

Revenue projections for INCY
Revenue projections for INCY

INCY's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 3.316000
forwardPE 11.050247
debtToEquity 1.063000
earningsGrowth 0.436000
revenueGrowth 0.278000
grossMargins 0.528850
operatingMargins 0.255720
trailingEps 6.410000
forwardEps 8.725660

Incyte Corporation's current ratio is 3.316, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as Incyte Corporation should not face any issues meeting its short-term liabilities with available resources.
INCY's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
Positive earnings and revenue growth for Incyte Corporation suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
INCY's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
INCY's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that INCY's financial performance will improve in the current financial year.

Price projections:

Price projections for INCY
Price projections for INCY

Price projections for INCY have gradually risen over time, signaling increased optimism about the company's future prospects. This steady upward revision reflects growing confidence in INCY's market potential.

Insider Transactions:

Insider Transactions for INCY
Insider Transactions for INCY


32 INCY shares were sold in recent transactions, with market price at 87.37906265258789.During the period under consideration, there were no sell transactions.The trend of more buys than sells at INCY's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.

Recommendation changes over time:

Recommendations trend for INCY
Recommendations trend for INCY


The analysts' recent buy bias for INCY indicates strong confidence in the stock's future performance. This could encourage more investors to view INCY as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.